Pictet Asset Management Holding Sa Biotechnology

Pictet Asset Management Holding Sa

$88 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
REGN Regeneron Pharmaceuticals, Inc.	$75.2B	$301 Million 0.34% of portfolio	286,545	Q3 2024 Reduced 2.46%
VRTX Vertex Pharmaceuticals Inc	$102B	$241 Million 0.27% of portfolio	518,003	Q3 2024 Reduced 8.05%
ARGX Argenx Se	$34.5B	$191 Million 0.22% of portfolio	351,603	Q3 2024 Added 14.09%
ALNY Alnylam Pharmaceuticals, Inc.	$30.2B	$183 Million 0.21% of portfolio	664,722	Q3 2024 Reduced 12.37%
INSM Insmed Inc	$9.54B	$136 Million 0.15% of portfolio	1,863,341	Q3 2024 Added 24.96%
SRPT Sarepta Therapeutics, Inc.	$10.4B	$131 Million 0.15% of portfolio	1,051,011	Q3 2024 Added 9.8%
CYTK Cytokinetics Inc	$4.6B	$110 Million 0.13% of portfolio	2,088,567	Q3 2024 Added 18.12%
BPMC Blueprint Medicines Corp	$5.38B	$108 Million 0.12% of portfolio	1,166,507	Q3 2024 Added 3.48%
PCVX Vaxcyte, Inc.	$5.13B	$89.2 Million 0.1% of portfolio	780,905	Q3 2024 Added 46.54%
VKTX Viking Therapeutics, Inc.	$3.24B	$86.2 Million 0.1% of portfolio	1,361,510	Q3 2024 Reduced 1.44%
TGTX Tg Therapeutics, Inc.	$4.68B	$83.8 Million 0.1% of portfolio	3,582,583	Q3 2024 Added 10.45%
BBIO Bridge Bio Pharma, Inc.	$3.93B	$71.4 Million 0.08% of portfolio	2,803,057	Q3 2024 Added 5.82%
BMRN Biomarin Pharmaceutical Inc	$12.2B	$64.6 Million 0.07% of portfolio	919,616	Q3 2024 Reduced 44.71%
NUVL Nuvalent, Inc.	$3.62B	$63.5 Million 0.07% of portfolio	621,133	Q3 2024 Added 9.18%
SWTX Spring Works Therapeutics, Inc.	$2.22B	$61.7 Million 0.07% of portfolio	1,925,918	Q3 2024 Added 18.9%
XENE Xenon Pharmaceuticals Inc.	$2.41B	$60.2 Million 0.07% of portfolio	1,528,814	Q3 2024 Added 3.33%
IDYA Ideaya Biosciences, Inc.	$1.23B	$60 Million 0.07% of portfolio	1,894,340	Q3 2024 Added 19.33%
IONS Ionis Pharmaceuticals Inc	$5.06B	$52.2 Million 0.06% of portfolio	1,303,501	Q3 2024 Reduced 45.91%
MRUS Merus N.V.	$1.92B	$50.6 Million 0.06% of portfolio	1,012,448	Q3 2024 Added 19.89%
INCY Incyte Corp	$15.3B	$50.1 Million 0.06% of portfolio	757,655	Q3 2024 Added 0.66%
CRNX Crinetics Pharmaceuticals, Inc.	$2.88B	$46.4 Million 0.05% of portfolio	908,149	Q3 2024 Added 201.84%
MRNA Moderna, Inc.	$15.4B	$43.6 Million 0.05% of portfolio	652,943	Q3 2024 Reduced 41.4%
DAWN Day One Biopharmaceuticals, Inc.	$940M	$41.5 Million 0.05% of portfolio	2,982,666	Q3 2024 Added 4.6%
NRIX Nurix Therapeutics, Inc.	$935M	$40.2 Million 0.05% of portfolio	1,788,530	Q3 2024 Added 52.41%
CLDX Celldex Therapeutics, Inc.	$1.18B	$38.7 Million 0.04% of portfolio	1,138,446	Q3 2024 Reduced 17.72%
RNA Avidity Biosciences, Inc.	$1.66B	$36.1 Million 0.04% of portfolio	786,480	Q3 2024 Added 107.08%
MIRM Mirum Pharmaceuticals, Inc.	$1.53B	$34.9 Million 0.04% of portfolio	895,690	Q3 2024 Added 2.35%
IMVT Immunovant, Inc.	$3.55B	$33.8 Million 0.04% of portfolio	1,230,309	Q3 2024 Added 4.72%
MDGL Madrigal Pharmaceuticals, Inc.	$5.28B	$32 Million 0.04% of portfolio	150,598	Q3 2024 Added 9.71%
LBPH Longboard Pharmaceuticals, Inc.	$815M	$30.6 Million 0.03% of portfolio	918,573	Q3 2024 Added 0.52%
RARE Ultragenyx Pharmaceutical Inc.	$3.1B	$28.9 Million 0.03% of portfolio	520,550	Q3 2024 Reduced 6.51%
NTLA Intellia Therapeutics, Inc.	$926M	$28.7 Million 0.03% of portfolio	1,394,911	Q3 2024 Added 87.48%
RCKT Rocket Pharmaceuticals, Inc.	$875M	$25.6 Million 0.03% of portfolio	1,386,705	Q3 2024 Added 13.07%
VERA Vera Therapeutics, Inc.	$1.15B	$25.3 Million 0.03% of portfolio	571,998	Q3 2024 Reduced 8.28%
JAZZ Jazz Pharmaceuticals PLC	$7.71B	$25.1 Million 0.03% of portfolio	225,215	Q3 2024 Reduced 5.74%
BGNE Bei Gene, Ltd.	$18.3B	$24.3 Million 0.03% of portfolio	108,129	Q3 2024 Reduced 0.65%
ETNB 89bio, Inc.	$369M	$24 Million 0.03% of portfolio	3,246,608	Q3 2024 Reduced 9.88%
VRDN Viridian Therapeutics, Inc.\De	$759M	$23.3 Million 0.03% of portfolio	1,025,337	Q3 2024 Added 0.32%
ASND Ascendis Pharma A/S	$7.61B	$23 Million 0.03% of portfolio	154,044	Q3 2024 Added 5.27%
NVO Novo Nordisk A S	$192B	$23 Million 0.03% of portfolio	192,948	Q3 2024 Added 0.4%
EXEL Exelixis, Inc.	$10.7B	$22.7 Million 0.03% of portfolio	874,470	Q3 2024 Reduced 5.55%
KRYS Krystal Biotech, Inc.	$4.23B	$21 Million 0.02% of portfolio	115,350	Q3 2024 Reduced 16.07%
OLMA Olema Pharmaceuticals, Inc.	$247M	$19.9 Million 0.02% of portfolio	1,667,459	Q3 2024 New
MLTX Moon Lake Immunotherapeutics	$1.93B	$18 Million 0.02% of portfolio	356,836	Q3 2024 Added 3.18%
AGIO Agios Pharmaceuticals, Inc.	$1.94B	$17.8 Million 0.02% of portfolio	400,849	Q3 2024 Reduced 5.02%
UTHR United Therapeutics Corp	$16.4B	$17.4 Million 0.02% of portfolio	48,680	Q3 2024 Reduced 15.36%
FOLD Amicus Therapeutics, Inc.	$2.75B	$17.4 Million 0.02% of portfolio	1,627,877	Q3 2024 Reduced 61.39%
RYTM Rhythm Pharmaceuticals, Inc.	$3.13B	$17.3 Million 0.02% of portfolio	329,339	Q3 2024 Reduced 58.92%
SMMT Summit Therapeutics Inc.	$3.6B	$15.1 Million 0.02% of portfolio	691,404	Q3 2024 Reduced 2.43%
PLRX Pliant Therapeutics, Inc.	$643M	$14.3 Million 0.02% of portfolio	1,279,717	Q3 2024 Added 7.02%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pictet Asset Management Holding Sa, based on Form 13F filings with the SEC.

News

Stay updated on Pictet Asset Management Holding Sa with notifications on news.